Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Conference item |
Language: | English |
Published: |
Elsevier
2017
|
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Conference item |
Language: | English |
Published: |
Elsevier
2017
|